A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer - Beyond the Abstract
January 2, 2024
We conducted a study to assess the safety and efficacy of relugolix combined with abiraterone acetate or apalutamide. We presented results from this ongoing, two-part, Phase I, 52-week, open-label cohort study in patients with advanced prostate cancer (NCT04666129), which evaluated relugolix in combination with abiraterone acetate and a corticosteroid (prednisone or methylprednisolone) in Part 1, and relugolix combined with apalutamide in Part 2.
Biographies:
Jose De La Cerda, MD, Urologist, Urology San Antonio, San Antonio, TX, USA
Biographies:
Jose De La Cerda, MD, Urologist, Urology San Antonio, San Antonio, TX, USA
Related Content:
A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer - Beyond the Abstract
A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer.
A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer - Beyond the Abstract
A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer.